【GPCR】GLP1R

Product Center > Cell lines > GPCR

【GPCR】GIPR

Product Center > Cell lines > GPCR

【Biosimilar Antibodies】GPCR

Product Center > Antibodies > Biosimilar Antibodies

【Insights】GLP-1R/GCGR/GIPR: Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis

2024-11-06

【Insights】GLP-1：Amgen’s MariTide Demonstrates 20% Weight Loss

2024-11-28

【Insights】Merck Enters into Exclusive Global GLP-1：License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

2024-12-19

【Insights】GLP:Eden Unveils the World's First Compounded GLP-1 Rx Gummy

2025-01-10

【Insights】GLP-1:Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug

2025-04-25

【Insights】After the GLP-1, where is the next breakthrough in weight-loss drugs?

2025-06-19

【Insights】What’s Next After GLP-1? ActRII Ignites a New Wave of High-Quality Weight Loss

2025-07-01

【Insights】GLP1R：Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

2025-07-31

【Insights】GLP-1R/GCGR/GIPR：Novo Nordisk Delivers Strong H1 2025 Results, Driven by Soaring GLP-1 Drug Sales

2025-08-07

【Insights】GLP-1R: Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

2025-09-28

【Insights】Could GDF15 Become the Next Super Target After PD-1 and GLP-1?

2025-12-17

【Insights】GLP-1 Landscape Shift: The Rise of Oral Weight-Loss Therapies

2026-04-15

【Product Center】Rat_GLP1R HEK-293 Cell Line

Product Center

【Product Center】H_GLP1R β-Arrestin Reporter CHO-K1 Cell Line

Product Center

【Product Center】Mouse_GLP1R GIPR CHO-K1 Cell Line

Product Center

【Product Center】Cynomolgus_GLP1R GIPR CHO-K1 Cell Line

Product Center

【Product Center】Mouse_GLP1R HEK-293 Cell Line

Product Center